The use of oral antidiabetic agents in primary care

Australian Family Physician

Volumn 36, Issue 6, 2007, Pages 477-480

  Weekes, Andrew John ^a   Thomas, Merlin C ^b,c  

^a Laboratories (Australia) Pty Ltd   (Australia)

^b Juvenile Diabetes Research Foundation   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; METFORMIN;

AGED; ARTICLE; CHRONIC KIDNEY FAILURE; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; STANDARD;

AGED; DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION REVIEW; FEMALE; GLOMERULAR FILTRATION RATE; GUIDELINE ADHERENCE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY FAILURE, CHRONIC; MALE; METFORMIN; PILOT PROJECTS; PRIMARY HEALTH CARE;

EID: 34548821939     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Thomas MC, Weekes AJ, Broadley OJ, Cooper Me, Mathew TH. The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust 2006;185:140-4.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
3. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E. Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 1995;12:149-55.
4. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-63.
5. Srivastava PM, Thomas MC, Calafiore P, MacIsaac RJ, Jerums G, Burrell LM. Diastolic dysfunction is associated with anaemia in patients with Type II diabetes. Clin Sci (Lond) 2006;110:109-16.
6. Macisaac RJ, Tsalamandris C, Thomas MC et al. Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia 2006;49:1686-9.
7. Thomas MC, Weekes AJ, Broadley OJ, Cooper ME. The assessment of kidney function by general practitioners in Australian patients with type 2 diabetes (NEFRON 2). MJA 2006;185:259-62.
8. Corsonello A, Pedone C, Corica F et al (Gruppo Italianodi Farmacovigilanza nell'Anziano). Concealed renal failure and adverse drug reactions in older patients with type 2 diabetes mellitus. J Gerontol A Biol Sci Med Sci. 2005;60:1147-51.
9. Harris P, Joyner B, Phillips P, Webster C. Diabetes management in general practice 2004/5. 10th edn. Canberra: Diabetes Australia/The Royal Australian College of General Practitioners, 2004.
10. Working Group for the Therapeutic Guidelines in Endocrinology. Therapeutic guidelines in endocrinology. 3rd edn. Melbourne: Therapeutic Guidelines Ltd, 2004.
11. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997;20:925-8.
12. Holstein A, Nahrwold D, Hinze S, Egberts EH. Contraindications to metformin therapy are largely disregarded. Diabet Med 1999;16:692-6.
13. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265-6.
14. Nisbet JC, Sturtevant JM, Prins JB. Metformin and serious adverse effects. Med J Aust 2004;180:53-4.
15. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;1:CD002967.
16. Tessier D, Dawson K, Tetrault JP, Bravo G, Meneilly GS. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994;11:974-80.
17. Schernthaner G, Grimaldi A, Di Mario U et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-42.
18. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735- 41.
19. Australian Institute of Health and Welfare. Medical labour force 2003. AIHW Cat.No.HWL32. Canberra: AIHW, 2005.
20. Charles J, Ng A, Miller G. Management of type 2 diabetes in Australian general practice. Aust Fam Physician 2006;35:378-9.
21. Davis TM, Jackson D, Davis WA, Bruce DG, Chubb P. The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study. Br J Clin Pharmacol 2001;52:137-44.